Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05580250 Withdrawn - Healthy Clinical Trials

A Study of LY3526318 in Healthy Male Japanese Participants

Start date: November 22, 2022
Phase: Phase 1
Study type: Interventional

This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: - Assess how safe and well tolerated LY3526318 is when given by mouth. - Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part.

NCT ID: NCT05451095 Withdrawn - Healthy Clinical Trials

A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine

Start date: November 7, 2022
Phase: Phase 1
Study type: Interventional

To investigate the effect of BI 474121 compared to placebo on ketamine-induced cognitive deficits to predict efficacy in patients with cognitive disorders.

NCT ID: NCT05252520 Withdrawn - Healthy Clinical Trials

A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Start date: May 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 following single ascending dose subcutaneous (SC) administration to healthy Chinese participants.

NCT ID: NCT05182047 Withdrawn - Healthy Clinical Trials

A Study of Butamirate Citrate Syrup Versus (vs) Sinecod Syrup (Vanilla) in Adult Healthy Study Volunteers

Start date: March 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate bioequivalence with respect to rate and extent of absorption of 2-phenylbuturic acid of the novel medication butamirate citrate syrup 1.5 milligrams per milliliter (mg/mL), and the medication sinecod syrup (vanilla) 1.5 mg/mL after single-dose administration in fasting condition by healthy volunteers.

NCT ID: NCT05159128 Withdrawn - Healthy Clinical Trials

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-75105186 after single ascending oral dose administration in healthy Japanese participants and after single oral dose administration in healthy Chinese participants.

NCT ID: NCT04997616 Withdrawn - Healthy Clinical Trials

Determination of Cannabinoid and Cannabinoid Metabolite Levels in Healthy Volunteers

Start date: January 3, 2023
Phase: Early Phase 1
Study type: Interventional

Levels of major cannabinoid and cannabinoid metabolites (i.e., CBD, CBD-OH) will be determined in the plasma of healthy volunteers following 10 days of Happy Lane Hemp Extract/CBD soft gels (25 mg per capsule) supplementation using liquid chromatography-mass spectrometry (LCMS).

NCT ID: NCT04941365 Withdrawn - Healthy Clinical Trials

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

SERPENTINE
Start date: July 7, 2022
Phase: N/A
Study type: Interventional

It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying spontaneous T cell-mediated immune response against their tumor (defined as immune surveillance) have higher chance to respond to therapies and display globally better prognosis. Conversely, patients whose tumor is characterized by immunosuppression, usually involving myeloid cells and chronic inflammation pathways, often undergo rapid progression and rarely benefit from therapy. Hence, capturing the immune features of individual tumors can help to predict disease course and tailor the therapeutic workup in clinical setting.

NCT ID: NCT04853524 Withdrawn - Healthy Clinical Trials

A Study of JNJ-56136379 in Healthy Participants

Start date: May 6, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of multiple-dose JNJ-56136379 on the single-dose pharmacokinetics (PK) of the combination of bictegravir (BIC), emtricitabine (FTC), tenofovir alafenamide (TAF) in healthy adult participants.

NCT ID: NCT04782661 Withdrawn - Healthy Clinical Trials

A Study of JNJ-70075200 in Healthy Participants

Start date: March 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate safety and tolerability of JNJ-70075200 compared with placebo after administration of single ascending doses of JNJ-70075200 as oral solution (Part 1); multiple ascending doses of JNJ-70075200, administered as oral solution over 14 consecutive days (Part 2); and the option of a single dose of JNJ-70075200 administered as an oral solid formulation (Part 3).

NCT ID: NCT04712006 Withdrawn - Healthy Clinical Trials

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

Start date: May 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmacokinetic following single subcutaneous administration of Dose 1 or Dose 2 of JNJ-64304500 in healthy Chinese adult participants.